Toboroz
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT05647265· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: John A. Ellerton (principal investigator)
Toboroz
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Alan K. Ikeda (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Khawaja S. Jahangir (principal investigator)
Fut, nem toboroz
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: John A. Ellerton (principal investigator)
Fut, nem toboroz
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· 3. fázis· Children's Oncology Group· Forrás
Toboroz
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Khawaja S. Jahangir (principal investigator)
Toboroz
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Forrás
Contact: Khawaja S. Jahangir (principal investigator)
Toboroz
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: John A. Ellerton (principal investigator)
Toboroz
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165· 3. fázis· Children's Oncology Group· Forrás
Contact: Alan K. Ikeda (principal investigator)
Toboroz
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673· NRG Oncology· Forrás
Contact: Khawaja S. Jahangir (principal investigator)
Fut, nem toboroz
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647· 2. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
NCT04548752· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
NCT04444921· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
NCT04334941· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
NCT04310007· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04092283· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT04134260· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
NCT04175912· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
NCT04242095· Alliance for Clinical Trials in Oncology· Forrás
Contact: Khawaja S. Jahangir (principal investigator)
Fut, nem toboroz
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
NCT03811015· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03793166· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03348631· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT03701282· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· 2/3. fázis· SWOG Cancer Research Network· Forrás
Contact: John A. Ellerton (principal investigator)
Fut, nem toboroz
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT03595124· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT03375320· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NCT03371719· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
NCT02642042· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Khawaja S. Jahangir (principal investigator)
Fut, nem toboroz
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
NCT02311933· 2. fázis· National Cancer Institute (NCI)· Forrás
Showing 50 of 64.